MRI Based Study to Assess Brain-gut Axis in Obesity

NCT ID: NCT05437653

Last Updated: 2022-06-29

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

40 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-03-28

Study Completion Date

2023-12-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The mechanism of neural communication between the brain and gut in the regulation of food intake is complex and not fully understood. Magnetic Resonance Imaging (MRI) is a powerful non-invasive imaging tool that allows studying the function of the brain and gut. The aim of this study is to develop MRI methods to combine brain and gut imaging in a single MRI scan session. The developed techniques will then be used to assess the brain-gut axis to a high fat drink compared with iso-caloric/iso-viscous/iso-volumetric carbohydrate drink in people with obesity and healthy weight participants. The findings could provide a possible explanation for why some people are heavier than others.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

20 healthy weight participant (18 Kg/m2\>BMI\<30Kg/m2) and 20 age- and sex- matched peoples with obesity (BMI \>30 Kg/m2) will be invited to a double-blinded two-way crossover MRI study, approximately 1 week apart, to assess the interplay between brain and gut to food intake.

Brain and gut MRI scans will be collected at fasted/baseline and at different time points postprandial for 120 mins using the 3T Ingenia Philips scanner. Brain measurements including resting state-fMRI, cerebral blood flow (CBF), and task-fMRI scans will be collected. During the task fMRI scan, images of high and low energy food pictures, and non-food control pictures will be presented. Food images are extensively used in fMRI studies to characterise the neural systems involved in processing the hedonic value of food as well as satiety and hunger signals. In addition to brain scans, sequences of gut scans will be collected to assess gastric volume, small bowel water content, and superior mesenteric artery (SMA) responses pre- and post-prandial. Blood samples will be collected to assess gut hormones (CCK, GLP1- PYY, ghrelin) insulin and glucose, triglycerides, free fatty acid levels at different timepoints. In addition, satiety and appetite scores will be collected using visual analogue scales. The total scan time including the fed and break times is around 3 hours.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Obesity

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Randomised parallel trial in human volunteers. Control (normal weight) group VS Obese group and High fat drink VS iso-caloric, iso-viscous Carbohydrate drink
Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

DOUBLE

Participants Outcome Assessors
This is a double-blinded study, and the study participant and assessor will be unaware of the nature of the drink. Subjects will be invited into 2 MRI scan visits to investigate the brain and gut responses (brain-gut axis) to a high fat drink and a carbohydrate drink. Drinks will be randomised across participants using research randomizer software (https://www.randomizer.org/).

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Control group

Healthy weight group ( same age and sex)

Group Type ACTIVE_COMPARATOR

Nutritional Drink A

Intervention Type OTHER

300 mL of a 22% high fat emulsion (Rapeseed oil, water, emulsifier)

Nutritional Drink B

Intervention Type OTHER

300 mL of isocaloric, iso-volumetric and iso-viscous carbohydrate drink (maltodextrin)

Obese group

Obese group

Group Type ACTIVE_COMPARATOR

Nutritional Drink A

Intervention Type OTHER

300 mL of a 22% high fat emulsion (Rapeseed oil, water, emulsifier)

Nutritional Drink B

Intervention Type OTHER

300 mL of isocaloric, iso-volumetric and iso-viscous carbohydrate drink (maltodextrin)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Nutritional Drink A

300 mL of a 22% high fat emulsion (Rapeseed oil, water, emulsifier)

Intervention Type OTHER

Nutritional Drink B

300 mL of isocaloric, iso-volumetric and iso-viscous carbohydrate drink (maltodextrin)

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Aged 18-45, male and female (females will have the study days arranged during the early phase of the menstrual cycle).
* Body mass index (BMI): normal weight participants ≥ 19 and ≤ 25 Kg/m2, and obese participants \> 30 Kg/m2
* Able to give voluntary written informed consent to participate in the study
* Able to understand the requirements of the study
* Apparently healthy: no medical conditions which might affect study measurements (judged by health questionnaire, and blood screening)

Exclusion Criteria

* Any reported history of neurological or gastrointestinal disorders
* Any reported history of surgery that could affect gastrointestinal function (e.g. colectomy, small bowel resection)
* Abnormal screening procedures including depression and eat restriction
* Laboratory results that are clinically significant, including diabetes, dyslipidemia, pancreatitis, or untreated hypertension.
* Contraindications for MRI scanning i.e. metallic implants, pacemakers, history of metallic foreign body in eye(s) and penetrating eye injury, assessed by standard MRI safety questionnaire.
* Under medication (expect aspirin/paracetamol), antibiotic or prescribed probiotic treatment in the past 12 weeks.
* Following a medically- or self-prescribed diet during the two weeks prior to the pre-study examination and until the end of the study.
* Reported weight loss or gain ≥ 10 % of bodyweight during the six months period before the pre-study examination
* Pregnancy or breastfeeding declared by candidate
* Smoking
* Left-handed assessed by handedness questionnaire. This is to control for brain's lateralisation effects (activation in one side of the brain) that may show variations between left and right handed participants.
* Participation in another clinical or research study within the previous 3 months of the study
* Cannot lie flat or exceeding the scanner bed weight limit of 250 kg.
* Poor understanding of the spoken and/or written English language
Minimum Eligible Age

18 Years

Maximum Eligible Age

45 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of Nottingham

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Sally Eldeghaidy, PhD

Role: PRINCIPAL_INVESTIGATOR

University of Nottingham

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University of Nottingham

Nottingham, , United Kingdom

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

United Kingdom

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Sally Eldeghaidy, PhD

Role: CONTACT

0115 84 66003

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Sally Eldeghaidy, PhD

Role: primary

0115 84 66003

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

19047

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Does What You Eat Affect Your Brain
NCT05626907 COMPLETED NA
Neuroimmune Mechanisms in Obesity
NCT05553405 WITHDRAWN PHASE1